NOVOMEDLINK™

This page contains information about Novo Nordisk products.

NovoLog® Mix 70/30 dosing for patients with type 2 diabetes uncontrolled on OADs

Dosing for patients with type 2 diabetes uncontrolled on OADs

*Continue metformin.
†Discontinue PM secretagogue with once-daily dosing and AM secretagogue with BID dosing.
‡One dose at a time (if PM glucose level is higher than AM FPG level, increase AM dose or vice versa).

Learn more about dosing

See how flexible dosing with NovoLog® Mix 70/30 can help your patients get to goal.

View eLearning presentation

Converting patients from human premix 70/30 to NovoLog® Mix 70/30 is simple using a 1:1 unit conversion

Unit-to-unit conversion to NovoLog® Mix 70/30

Dosing for patients with type 2 diabetes uncontrolled on OADs

In a subgroup analysis from the IMPROVE™ study, more patients achieved a target A1C <7% when switching unit-for-unit than when switching to a lower or higher dose.1

Dose regimens of NovoLog® Mix 70/30 will vary among patients and should be determined by the health care professional familiar with the patient’s recommended glucose treatment goals, metabolic needs, eating habits, and other lifestyle variables.

Any change of insulin should be made cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, species, or method of manufacture may result in the need for a change in dosage.

When writing a prescription for your patient, make sure to write out NOVOLOG® MIX 70/30 FLEXPEN®

More units. Same co-pay.

One prescription for one box of NovoLog® Mix 70/30 FlexPen® provides 50% more insulin than a vial/syringe for the same co-pay on most managed care plans.2

  • A prescription for one box of FlexPen® (1 box of 5 pens) = 1500 units
  • One prescription for vial = 1000 units

Tools to help your patients get started

Co-Pay Cards

Help patients get instant savings at their pharmacies. The Co-Pay Card saves your patients money by providing a reduced co-pay for eligible patients.

Cornerstones4Care™

A personalized program to help people with diabetes reach their goals.

Related Support

Watch Clinician's Forum: Building Blocks for Diabetes Management

Javier Morales, MD, and Joseph Tibaldi, MD, provide recommendations for bringing a hypothetical patient’s glucose levels under control using NovoLog® Mix 70/30.

Request samples

Order samples of NovoLog® Mix 70/30 FlexPen® and the NovoTwist® needle.

Up Next

Learn about dosing with the NovoLog® Mix 70/30 FlexPen®

References:

  1. Shah S, Benroubi M, Borzi V, et al; IMPROVE Study Group Expert Panel. Safety and effectiveness of biphasic insulin aspart 30⁄70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study. Int J Clin Pract. 2009;63(4):574-582.
  2. Data on file, Novo Nordisk, Inc., Princeton, NJ.

  1. NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Indications and Usage

    NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus.

    Important Limitations of Use:
    In premix insulins, such as NovoLog® Mix 70/30, the proportions of rapid acting and long acting insulins are fixed and do not allow for basal versus prandial dose adjustments.

    NovoLog® Mix 70/30 Important Safety Information

    NovoLog® Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® Mix 70/30 or one of its excipients.

    NovoLog® Mix 70/30 has a faster onset of action than human insulin premix 70/30 and should be dosed within 15 minutes before meal initiation for patients with type 1 diabetes. For patients with type 2 diabetes, dosing should occur within 15 minutes before or after meal initiation.

    NovoLog® Mix 70/30 should not be administered intravenously or used in insulin infusion pumps. NovoLog® Mix 70/30 should not be mixed with any other insulin product.

    Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog® Mix 70/30. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin should be made cautiously and only under medical supervision.

    Needles and NovoLog® Mix 70/30 FlexPen® must not be shared.

    Severe, life-threatening generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog® Mix 70/30. Adverse reactions observed with NovoLog® Mix 70/30 include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® Mix 70/30 requirements may be reduced in patients with renal impairment or hepatic impairment.

    The safety and effectiveness of NovoLog® Mix 70/30 has not been established in pediatric patients. Clinical studies of NovoLog® Mix 70/30 did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients.

    The significance, with respect to the long-term clinical sequelae of diabetes, of the differences in postprandial hyperglycemia between treatment groups has not been established.

    Please click hereclick here for Prescribing Information.

FlexPen®, NovoLog®, and NovoTwist® are registered trademarks of Novo Nordisk A/S. Cornerstones4Care™ and NovoMedLink™ are trademarks of Novo Nordisk A/S.